Related references
Note: Only part of the references are listed.First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
Carol Moreno et al.
HAEMATOLOGICA (2022)
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia
Jeff P. Sharman et al.
LEUKEMIA (2022)
Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics
Joan Montero et al.
CANCER DISCOVERY (2022)
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model
Inhye E. Ahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
Remi Letestu et al.
LEUKEMIA (2021)
Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy
Jennifer A. Woyach et al.
BLOOD (2021)
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
Othman Al-Sawaf et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PLUS EITHER CHLORAMBUCIL OR VENETOCLAX ‐ UPDATED ANALYSIS OF THE CLL14 TRIAL
E Tausch et al.
HEMATOLOGICAL ONCOLOGY (2021)
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia
Johannes Bloehdorn et al.
NATURE COMMUNICATIONS (2021)
Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia
Junyan Lu et al.
NATURE CANCER (2021)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
Treatment of Chronic Lymphocytic Leukemia
Jan A. Burger
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
Arnon P. Kater et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
Othman Al-Sawaf et al.
LANCET ONCOLOGY (2020)
Managing toxicities of Bruton tyrosine kinase inhibitors
Andrew Lipsky et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia
Eugen Tausch et al.
HAEMATOLOGICA (2019)
Determining cell type abundance and expression from bulk tissues with digital cytometry
Aaron M. Newman et al.
NATURE BIOTECHNOLOGY (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
K. Fischer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab
Anton W. Langerak et al.
BLOOD (2019)
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
Arnon P. Kater et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Piers Blombery et al.
CANCER DISCOVERY (2019)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
Stephan Stilgenbauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. F. Seymour et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Carmen D. Herling et al.
NATURE COMMUNICATIONS (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Avi Ashkenazi et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group
Gabor Kovacs et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Stephan Stilgenbauer et al.
LANCET ONCOLOGY (2016)
Mutations driving CLL and their evolution in progression and relapse
Dan A. Landau et al.
NATURE (2015)
GSVA: gene set variation analysis for microarray and RNA-Seq data
Sonja Haenzelmann et al.
BMC BIOINFORMATICS (2013)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
